主要文件

查看所有文档

Y0001108

丁丙诺啡

Name: 丁丙诺啡
Brand: SIAL

European Pharmacopoeia (EP) Reference Standard

登录查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式（希尔记法）:

C₂₉H₄₁NO₄

化学文摘社编号:

52485-79-7

分子量:

467.64

UNSPSC Code:

41116107

NACRES:

NA.24

技术服务

需要帮助？我们经验丰富的科学家团队随时乐意为您服务。

让我们为您提供帮助

属性

grade

pharmaceutical primary standard

API family

buprenorphine

manufacturer/tradename

EDQM

drug control

kontrollierte Droge in Deutschland, regulated under CDSA - not available from Sigma-Aldrich Canada; psicótropo (Spain); Decreto Lei 15/93: Tabela IIC (Portugal); Pszichotróp anyag / Psychotropic Substance (Hungary), 78/2022. (XII. 28.) BM rendelet

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

[Cl-].N2([C@H]3[C@]54[C@@]6([C@@H](Oc7c6c(ccc7O)C3)C([C@H](C5)[C@](O)(C(C)(C)C)C)(CC4)OC)CC2)CC1CC1.[H+]

InChI

1S/C29H41NO4.ClH/c1-25(2,3)26(4,32)20-15-27-10-11-29(20,33-5)24-28(27)12-13-30(16-17-6-7-17)21(27)14-18-8-9-19(31)23(34-24)22(18)28;/h8-9,17,20-21,24,31-32H,6-7,10-16H2,1-5H3;1H/t20-,21-,24-,26+,27-,28+,29?;/m1./s1

InChI key

UAIXRPCCYXNJMQ-CHLZSUIASA-N

说明

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Buprenorphine EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

Legal Information

German
Dieses Produkt fällt unter das Betäubungsmittelgesetz (BtMG). Für eine Bestellung dieses Produktes ist eine Erlaubnis nach § 3 BtMG zwingend erforderlich, es sei denn, es greift eine Ausnahme von der Erlaubnispflicht nach § 4 oder § 26 BtMG.

English
This product is subject to the German Narcotics Act. A permit under Section 3 of the German Narcotics Act is mandatory for ordering this product unless an exemption from the permit requirement under Section 4 or Section 26 of the German Narcotics Act applies.

pictograms

GHS06

signalword

Danger

hcodes

H301,H336,H413

pcodes

P261 - P264 - P271 - P273 - P301 + P310 - P304 + P340 + P312

Hazard Classifications

Acute Tox. 3 Oral - Aquatic Chronic 4 - STOT SE 3

target_organs

Central nervous system

存储类别

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable

法规信息

新产品

此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助，请联系客户支持

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

MicroRNA-374a protects against myocardial ischemia-reperfusion injury in mice by targeting the MAPK6 pathway.

Zhao-Qi Huang et al.

Life sciences, 232, 116619-116619 (2019-07-03)

Clinical treatment strategies for patients with myocardial ischemia typically include coronary artery recanalization to restore myocardial blood supply. However, myocardial reperfusion insult often induces oxidative stress and inflammation, which further leads to apoptosis and necrosis of myocardial cells. Increasing evidence

Endothelial Hypoxia-Inducible Factor-1α Is Required for Vascular Repair and Resolution of Inflammatory Lung Injury through Forkhead Box Protein M1.

Xiaojia Huang et al.

The American journal of pathology, 189(8), 1664-1679 (2019-05-24)

Endothelial barrier dysfunction is a central factor in the pathogenesis of persistent lung inflammation and protein-rich edema formation, the hallmarks of acute respiratory distress syndrome. However, little is known about the molecular mechanisms that are responsible for vascular repair and

Relapse to opioid use in opioid-dependent individuals released from compulsory drug detention centres compared with those from voluntary methadone treatment centres in Malaysia: a two-arm, prospective observational study.

Martin P Wegman et al.

The Lancet. Global health, 5(2), e198-e207 (2016-12-15)

Detention of people who use drugs into compulsory drug detention centres (CDDCs) is common throughout East and Southeast Asia. Evidence-based pharmacological therapies for treating substance use disorders, such as opioid agonist treatments with methadone, are generally unavailable in these settings.

查看所有相关文献

全球贸易项目编号

货号	GTIN
Y0001108	04061833797020